Dapagliflozin vs Metformin: HbA1c, Weight and CV Effects
Metformin lowers HbA1c 1.0-1.5% with proven CV benefit; dapagliflozin lowers 0.5-0.8% but adds heart and kidney protection. No head-to-head trial exists.
Insulin Blood Sugar: Head-to-Head Comparisons
39 source-based articles maintained by the HealthRX.com Editorial Team.
39articles
3topic areas covered
May 26, 2026latest review
Insulin Blood Sugar: Head-to-Head Comparisons library
Showing 39 of 39 clinical reviews.
Farxiga vs Lantus: Cost, Access, and Clinical Comparison
Head-to-head comparison of Farxiga (dapagliflozin) and Lantus (insulin glargine) covering cost, insurance access, clinical trial outcomes, and prescribing considerations for blood sugar management.
Farxiga vs Lantus: Head-to-Head Efficacy Comparison
Clinical comparison of dapagliflozin (Farxiga) and insulin glargine (Lantus) for blood sugar control, cardiovascular outcomes, and weight effects. Evidence from DAPA-HF, ORIGIN, and major trials.
Farxiga vs Lantus: Side-Effect Profile Head-to-Head
A clinical comparison of dapagliflozin (Farxiga) and insulin glargine (Lantus) side effects, including hypoglycemia risk, genital infections, weight changes, and cardiovascular safety data from DAPA-HF and ORIGIN.
Farxiga vs Lantus: Switching Between Dapagliflozin and Insulin Glargine
Clinical comparison of Farxiga (dapagliflozin) and Lantus (insulin glargine) for type 2 diabetes, including when and how to switch between them safely.
Farxiga vs Metformin Cost and Access Head-to-Head
A clinical comparison of dapagliflozin (Farxiga) vs metformin on cost, access, efficacy, and safety, with trial data, guideline quotes, and a decision framework for prescribers and patients.
Farxiga vs Metformin Side Effects: A Head-to-Head Profile
A detailed clinical comparison of dapagliflozin (Farxiga) and metformin side-effect profiles, including cardiovascular outcomes, GI tolerability, and prescribing guidance from named trials and guidelines.
Farxiga vs Metformin: Which One and When to Switch
Farxiga and metformin work differently and are often combined, not swapped. See A1C effects, CV and kidney benefits, and how to switch safely.
Farxiga vs Tresiba Cost and Access Head-to-Head
A clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) covering mechanism, efficacy, safety, cost, and insurance access, prepared by the HealthRX.com Editorial Team.
Farxiga vs Tresiba: Head-to-Head Efficacy Comparison
A clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) for blood sugar control, cardiovascular outcomes, and weight effects, with trial data from DAPA-HF and DEVOTE.
Farxiga vs Tresiba: Side-Effect Profile Head-to-Head
A clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) side effects, including hypoglycemia risk, genital infections, DKA, weight changes, and cardiovascular safety data from DAPA-HF and DEVOTE.
Farxiga vs Tresiba: Switching Between Dapagliflozin and Insulin Degludec
Clinical comparison of Farxiga (dapagliflozin) and Tresiba (insulin degludec), including when and how to switch between them, trial evidence from DAPA-HF and DEVOTE, and practical guidance for patients with type 2 diabetes.
Jardiance vs Farxiga Head-to-Head Efficacy: What the Trials Actually Show
A clinical comparison of empagliflozin (Jardiance) and dapagliflozin (Farxiga) covering cardiovascular outcomes, heart failure, kidney protection, blood sugar control, and how to choose between them.
Jardiance vs Farxiga Side Effects: Empagliflozin vs Dapagliflozin Head-to-Head
A detailed comparison of side-effect profiles for Jardiance (empagliflozin) and Farxiga (dapagliflozin), including genital infections, DKA risk, cardiovascular safety, and renal effects drawn from major clinical trials.
Jardiance vs Farxiga: Cost and Access Head-to-Head
A detailed comparison of Jardiance (empagliflozin) and Farxiga (dapagliflozin) covering pricing, insurance coverage, patient assistance programs, and clinical evidence to help you choose the right SGLT2 inhibitor.
Jardiance vs Farxiga: Switching Between Empagliflozin and Dapagliflozin
Evidence-based comparison of Jardiance (empagliflozin) and Farxiga (dapagliflozin), including when and how to switch between SGLT2 inhibitors safely.
Jardiance vs Lantus Cost and Access Head-to-Head
A clinical and cost comparison of empagliflozin (Jardiance) vs insulin glargine (Lantus) for type 2 diabetes, covering trial evidence, pricing, insurance access, and who benefits from each drug.
Jardiance vs Lantus Side-Effect Profile: A Head-to-Head Comparison
Compare the side-effect profiles of Jardiance (empagliflozin) and Lantus (insulin glargine) using data from EMPA-REG OUTCOME, ORIGIN, and current clinical guidelines to help patients and clinicians make informed therapy decisions.
Jardiance vs Lantus: Empagliflozin vs Insulin Glargine Efficacy Compared
A clinical comparison of Jardiance (empagliflozin) and Lantus (insulin glargine) across HbA1c reduction, cardiovascular outcomes, weight effects, and hypoglycemia risk in type 2 diabetes.
Jardiance vs Lantus: Switching Between Empagliflozin and Insulin Glargine
Clinical comparison of Jardiance (empagliflozin) and Lantus (insulin glargine) for type 2 diabetes, including when and how to switch between them safely.
Jardiance vs Metformin: Cost and Access Head-to-Head
A detailed comparison of Jardiance (empagliflozin) and Metformin covering drug costs, insurance coverage, generic availability, cardiovascular outcomes, and prescribing access for type 2 diabetes.
Jardiance vs Metformin: Head-to-Head Efficacy Compared
An evidence-based comparison of Jardiance (empagliflozin) and Metformin for type 2 diabetes, covering HbA1c reduction, cardiovascular outcomes, weight loss, and renal protection from major clinical trials.
Jardiance vs Metformin: Side-Effect Profile Head-to-Head
A clinical comparison of empagliflozin (Jardiance) and metformin side effects, including GI tolerance, genital infections, cardiovascular outcomes, and weight changes from EMPA-REG OUTCOME and UKPDS 34.
Jardiance vs Metformin: Switching Between Them Safely
A clinical guide to switching between Jardiance (empagliflozin) and metformin, covering when to switch, how to transition, expected A1C changes, side effects, and what your prescriber considers before making the change.
Jardiance vs Tresiba: Cost and Access Head-to-Head
A detailed comparison of Jardiance (empagliflozin) and Tresiba (insulin degludec) covering cost, insurance coverage, patient assistance programs, clinical trial data, and access strategies for people with type 2 diabetes.
Jardiance vs Tresiba: Head-to-Head Efficacy Comparison
Evidence-based comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) for type 2 diabetes, covering HbA1c reduction, cardiovascular outcomes, weight effects, and hypoglycemia risk from EMPA-REG OUTCOME and DEVOTE trials.
Jardiance vs Tresiba: Side-Effect Profile Head-to-Head
A cross-trial comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) side effects, covering hypoglycemia, genital infections, cardiovascular outcomes, and weight changes in type 2 diabetes.
Jardiance vs Tresiba: Switching Between Empagliflozin and Insulin Degludec
A clinical comparison of Jardiance (empagliflozin) and Tresiba (insulin degludec), including when switching between them makes sense, trial evidence, and practical guidance for patients with type 2 diabetes.
Lantus vs Tresiba: Cost and Access Head-to-Head
A clinical and financial comparison of insulin glargine (Lantus) and insulin degludec (Tresiba), covering efficacy, hypoglycemia risk, WAC pricing, insurance formulary placement, and patient assistance programs.
Lantus vs Tresiba: Head-to-Head Efficacy Compared
Clinical comparison of insulin glargine (Lantus) and insulin degludec (Tresiba) across HbA1c reduction, hypoglycemia rates, cardiovascular outcomes, and real-world effectiveness data.
Lantus vs Tresiba: Switching Between Insulin Glargine and Insulin Degludec
Evidence-based comparison of Lantus (insulin glargine) and Tresiba (insulin degludec), including how to switch safely, dosing equivalence, hypoglycemia risk, and clinical trial data from ORIGIN and DEVOTE.
Metformin vs Lantus (Insulin Glargine): Head-to-Head Efficacy Comparison
Evidence-based comparison of metformin and insulin glargine (Lantus) for blood sugar control, including HbA1c reduction, weight effects, cardiovascular outcomes, and guideline recommendations.
Metformin vs Lantus (Insulin Glargine): Side-Effect Profile Head-to-Head
A clinical comparison of metformin and Lantus (insulin glargine) side effects, including GI symptoms, hypoglycemia risk, weight changes, and long-term safety data from UKPDS 34 and ORIGIN.
Metformin vs Lantus (Insulin Glargine): Switching Between Them
Clinical comparison of metformin and Lantus (insulin glargine) for blood sugar control, including when and how to switch between them, trial evidence from UKPDS 34 and ORIGIN, and practical dosing guidance.
Metformin vs Lantus Cost and Access Head-to-Head
A clinical comparison of metformin and insulin glargine (Lantus) on cost, access, efficacy, and safety, with real trial data, pricing benchmarks, and prescribing guidance.
Metformin vs Tresiba (Insulin Degludec): Cost and Access Head-to-Head
A clinical comparison of metformin and Tresiba (insulin degludec) covering cost, insurance access, efficacy data from UKPDS 34 and DEVOTE, and practical prescribing considerations for type 2 diabetes.
Metformin vs Tresiba (Insulin Degludec): Head-to-Head Efficacy Comparison
A clinical comparison of metformin and Tresiba (insulin degludec) for blood sugar control, covering HbA1c reduction, weight effects, hypoglycemia risk, and guideline positioning.
Metformin vs Tresiba (Insulin Degludec): Side-Effect Profile Head-to-Head
A detailed comparison of metformin and Tresiba (insulin degludec) side effects, including GI tolerance, hypoglycemia risk, weight changes, and cardiovascular safety data from UKPDS 34 and DEVOTE.
Metformin vs Tresiba (Insulin Degludec): Switching Between Them
A clinical comparison of metformin and Tresiba (insulin degludec), including when and how to switch between them, efficacy data from UKPDS 34 and DEVOTE, and practical guidance for patients with type 2 diabetes.